HomeCompareSHPMF vs PFE

SHPMF vs PFE: Dividend Comparison 2026

SHPMF yields 3.81% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SHPMF wins by $1402.75M in total portfolio value
10 years
SHPMF
SHPMF
● Live price
3.81%
Share price
$1.46
Annual div
$0.06
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1402.80M
Annual income
$1,335,511,443.90
Full SHPMF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SHPMF vs PFE

📍 SHPMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSHPMFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SHPMF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SHPMF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SHPMF
Annual income on $10K today (after 15% tax)
$324.09/yr
After 10yr DRIP, annual income (after tax)
$1,135,184,727.32/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SHPMF beats the other by $1,135,162,407.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SHPMF + PFE for your $10,000?

SHPMF: 50%PFE: 50%
100% PFE50/50100% SHPMF
Portfolio after 10yr
$701.43M
Annual income
$667,768,851.31/yr
Blended yield
95.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SHPMF
No analyst data
Altman Z
2.0
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SHPMF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSHPMFPFE
Forward yield3.81%6.13%
Annual dividend / share$0.06$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$1402.80M$49.6K
Annual income after 10y$1,335,511,443.90$26,258.71
Total dividends collected$1397.96M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SHPMF vs PFE ($10,000, DRIP)

YearSHPMF PortfolioSHPMF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,463$762.55$9,153$693.39+$2.3KSHPMF
2$13,899$1,633.80$8,593$849.25+$5.3KSHPMF
3$18,575$3,702.87$8,336$1,066.78+$10.2KSHPMF
4$29,124$9,249.68$8,437$1,384.80+$20.7KSHPMF
5$58,272$27,108.94$9,013$1,875.40+$49.3KSHPMF
6$163,733$101,382.29$10,306$2,680.72+$153.4KSHPMF
7$707,653$532,457.85$12,820$4,101.38+$694.8KSHPMF
8$5,058,632$4,301,444.15$17,673$6,826.70+$5.04MSHPMF
9$62,887,016$57,474,279.06$27,543$12,591.86+$62.86MSHPMF
10$1,402,800,551$1,335,511,443.90$49,560$26,258.71+$1402.75MSHPMF

SHPMF vs PFE: Complete Analysis 2026

SHPMFStock

Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People's Republic of China. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including oncology, cerebrocardiovascular, CNS, general infection, immunology, digestive and metabolism, and respiratory. It provides approximately 700 varieties of drugs. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores; online drug business; and provision of consulting services, assets management operations, as well as clinical trials, medical aid, physicians and patients' education, e-prescription management, and remote and cloud hospitals. Further, the company manufactures and trades in medicines. It operates approximately 2,000 retail chain pharmacies in 24 provinces. The company was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.

Full SHPMF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SHPMF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SHPMF vs SCHDSHPMF vs JEPISHPMF vs OSHPMF vs KOSHPMF vs MAINSHPMF vs JNJSHPMF vs MRKSHPMF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.